Hyperemesis in a Young Woman: Diagnosis

The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

Recurrent C difficile requires pulse vancomycin therapy; fecal microbiota transplant shows promise.

Your daily dose of the clinical news you may have missed.

The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.

Your daily dose of the clinical news you may have missed.

Marketed as Omvoh, the therapy is already approved as a first-in-class treatment for moderately to severely active ulcerative colitis.